Between 2026 and 2036, the therapeutic landscape for Pompe disease is expected to evolve significantly as a pipeline of innovative candidates moves through clinical trials. While traditional enzyme replacement therapy (ERT) has long served as the standard of care, companies including Shionogi, Maze Therapeutics, Astellas Pharma, and AskBio are introducing novel mechanisms to address persistent unmet needs. Among these, investigational therapies like MZE001, AT845, and AB-1009 aim to improve clinical outcomes by reducing glycogen accumulation and delivering functional gene copies directly to muscle cells.

The United States currently leads the market, accounting for approximately 66% of diagnosed prevalent cases across the seven major markets studied. This dominance is bolstered by robust genetic testing and diagnostic infrastructure. Industry analysts point to a clear trend: patients are increasingly transitioning from first-generation treatments to newer, more efficient options like NEXVIAZYME. The integration of gene therapy and oral inhibitors is projected to further reshape this environment, offering long-term management solutions that could fundamentally alter the prognosis for patients worldwide.